[Intra and extra hepatic cholangiocarcinomas radiation therapy].
Place de la radiothérapie des cholangiocarcinomes intra- et extrahépatiques.
Biliary duct cancer
Cholangiocarcinome
Cholangiocarcnoma
Radiation oncology
Radiotherapy
Radiothérapie
Revue
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
15
04
2020
revised:
09
06
2020
accepted:
13
06
2020
pubmed:
12
1
2021
medline:
7
4
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Cholangiocarcinomas are digestive tumors whose incidence remains low and have poor prognosis. The benefits of adjuvant radiochemotherapy and radiotherapy have never been demonstrated in any phase III randomized controlled trial. Chemotherapy with capecitabine 6 months is the standard of care in adjuvant setting. Radiochemotherapy is validated in R1 patients. It is not recommended in neoadjuvant situations given the lack of evidence. Chemotherapy and radiochemotherapy are validated in adjuvant or locally advanced diseases. Stereotactic radiation therapy offers an interesting perspective, at the cost of significant digestive toxicities, requiring evaluation in randomized trials.
Identifiants
pubmed: 33423966
pii: S1278-3218(20)30340-1
doi: 10.1016/j.canrad.2020.06.039
pii:
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Capecitabine
6804DJ8Z9U
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
175-181Informations de copyright
Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.